Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Feb;9(2):415-417.
doi: 10.21037/tcr.2020.01.25.

Towards understanding androgen receptor-independent prostate cancer: an evolving paradigm

Jianfu Zhou  1   2   3 , Yuliang Wang  3 , Songtao Xiang  1 , Franky L Chan  3
Affiliations
Editorial

Towards understanding androgen receptor-independent prostate cancer: an evolving paradigm

Jianfu Zhou et al. Transl Cancer Res. 2020 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2020.01.25). The authors have no conflicts of interest to declare.

Comment on

  • The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.
    Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC. Liu Y, et al. Sci Transl Med. 2019 Jul 31;11(503):eaaw4993. doi: 10.1126/scitranslmed.aaw4993. Sci Transl Med. 2019. PMID: 31366581 Free PMC article.

References

    1. Karantanos T, Evans CP, Tombal B, et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol 2015;67:470-9. 10.1016/j.eururo.2014.09.049 - DOI - PMC - PubMed
    1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005. 10.1056/NEJMoa1014618 - DOI - PMC - PubMed
    1. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90. 10.1126/science.1168175 - DOI - PMC - PubMed
    1. Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol 2018;15:271-86. 10.1038/nrurol.2018.22 - DOI - PubMed
    1. Bluemn EG, Coleman IM, Lucas JM, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 2017;32:474-89. e6. - PMC - PubMed